Abamune – Abacavir Sulfate (Ziagen Generic)

Abamune Abacavir ziagen
Abamune-L tablets are used to slow down the progression of HIV infection which can lead to AIDS and other related illnesses. Abamune-L tablets do not cure AIDS or destroy the HIV virus, but rather delay any further damage to the immune system by stopping production of new viruses.

Brand Name: Tibofem
Generic Name: Tibolone 2.5mg
Contents: Tibolone 2.5mg
Form: Tablet
Manufactured By: Cipla
Packing: Price Per Tablet

Price Per Pack of 30 Tablets
Possible side effects of Abamune (Abacavir)
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your physician if any of these most COMMON side effects persist or become bothersome:

  • Exhaustion;
  • flushing;
  • general body discomfort;
  • headache;
  • joint pain;
  • lack of energy;
  • loss of appetite;
  • mouth sores;
  • muscle aches;
  • redness of the eyes or swelling of the conjunctiva;
  • severe muscle pain or cramping;
  • sleeplessness;
  • swelling;
  • unusual weakness.

Seek medical attention right away if any of these SEVERE side effects occur:

  • Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue);
  • abnormal skin sensations;
  • achiness;
  • chest pain;
  • cough;
  • diarrhea;
  • extreme tiredness;
  • fainting;
  • fever;
  • flu-like illness;
  • generally ill feeling;
  • nausea;
  • severe dizziness;
  • shortness of breath;
  • sore throat;
  • stomach pain;
  • vomiting.

This is not a complete list of all side effects that may occur. If you have questions or need medical advice about side effects, contact your physician or physician.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Serious and sometimes fatal hypersensitivity reactions have been associated with ABAMUNE and other abacavir-containing products. Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir. Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.

HLA-B*5701-negative patients may develop a hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients. Regardless of HLA-B*5701 status, permanently discontinue ABAMUNE if hypersensitivity cannot be ruled out, even when other diagnoses are possible.

Important information on signs and symptoms of hypersensitivity, as well as clinical management, is presented below:

Signs and Symptoms of Hypersensitivity : Hypersensitivity to abacavir is a multi-organ clinical syndrome usually characterized by a sign or symptom in two or more of the following groups.

Group 1: Fever

Group 2: Rash

Group 3: Gastrointestinal (including nausea, vomiting, diarrhea, or abdominal pain)

Group 4: Constitutional (including generalized malaise, fatigue, or achiness)

Group 5: Respiratory (including dyspnea, cough, or pharyngitis)

Hypersensitivity to abacavir following the presentation of a single sign or symptom has been reported infrequently.

Hypersensitivity to abacavir was reported in approximately 8% of 2,670 patients (n = 206) in 9 clinical trials (range: 2% to 9%). Symptoms usually appeared within the first 6 weeks of treatment with abacavir, although the reaction may occur at any time during therapy. Median time to onset was 9 days; 89% appeared within the first 6 weeks; 95% of patients reported symptoms from two or more of the five groups listed above .

Clinical Management of Hypersensitivity: Discontinue ABAMUNE as soon as a hypersensitivity reaction is suspected. To minimize the risk of a life-threatening hypersensitivity reaction, permanently discontinue ABAMUNE  if hypersensitivity cannot be ruled out, even when other diagnoses are possible (e.g., acute onset respiratory diseases such as pneumonia, bronchitis, pharyngitis, or influenza; gastroenteritis; or reactions to other medications). Following a hypersensitivity reaction to abacavir, never restart ABAMUNE or any other abacavir-containing product because more severe symptoms can occur within hours and may include life-threatening hypotension and death.

When therapy with ABAMUNE has been discontinued for reasons other than symptoms of a hypersensitivity reaction, and if reinitiation of ABAMUNE or any other abacavir-containing product is under consideration, carefully evaluate the reason for discontinuation of ABAMUNE to ensure that the patient did not have symptoms of a hypersensitivity reaction. If the patient is of unknown HLA-B*5701 status, screening for the allele is recommended prior to reinitiation of ABAMUNE .

If hypersensitivity cannot be ruled out, DO NOT reintroduce ABAMUNE or any other abacavir-containing product. Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.

If symptoms consistent with hypersensitivity are not identified, reintroduction can be undertaken with continued monitoring for symptoms of a hypersensitivity reaction. Make patients aware that a hypersensitivity reaction can occur with reintroduction of ABAMUNE or any other abacavir-containing product and that reintroduction of ABAMUNE or any other abacavir-containing product needs to be undertaken only if medical care can be readily accessed by the patient or others.

OVERDOSAGE
There is no known antidote for abacavir.It is not known whether abacavir can be removed by peritoneal dialysis or hemodialysis.
Hiv aids drugs Quick Delivery to United Kingdom, Netherland, Hungary, Sweden, Serbia, Austria,Poland,Slovakia,United States, Georgia, Italy, Armenia, Philippines, Malaysia, USA, Canada, UK, Australia & other countries. Delivery By EMS, DHL, FEDEX, TNT, US